Curis (CRIS) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Pipeline overview and strategic focus

• Emavusertib, a first-in-class IRAK4 inhibitor, is the primary focus, with over 200 patients dosed across NHL, AML, and solid tumor studies.

• Efforts are concentrated on NHL and AML, with expansion into solid tumors through academic and NCI partnerships.

• The company prioritizes indications with high unmet need and sensitivity to TLR signaling, such as Waldenstrom's and ABC DLBCL.

• Five investigator-sponsored trials in solid tumors are ongoing, with preliminary data expected in 2025.

• Strong IP position with composition of matter protection until 2035.

NHL clinical development and results

• Emavusertib targets the TLR pathway, complementing BTK inhibitors in NHL.

• Combination with ibrutinib in primary CNS lymphoma shows a 50% objective response rate in relapsed/refractory patients.

• Monotherapy and combination data support the mechanism of dual pathway inhibition for deeper responses.

• Safety profile is favorable, with no dose-limiting toxicities at 200 mg BID in combination studies.

• Plans to expand into additional NHL subtypes and pursue partnerships for broader commercialization.

AML clinical development and results

• IRAK4 is expressed in nearly all AML patients and is not addressed by current standard of care.

• Emavusertib demonstrates single-agent activity across AML populations, with enhanced efficacy in FLT3-mutated patients.

• Combination of IRAK4 and FLT3 inhibition in one molecule leads to deeper and longer responses.

• Encouraging results in heavily pretreated FLT3 AML patients, including durable responses and successful transplants.

• Frontline AML study with triple combination (emavusertib, azacitidine, venetoclax) is underway, focusing on safety and MRD-negative conversion.